444 related articles for article (PubMed ID: 20353833)
1. Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation.
Larsen ME; Kornblit B; Larsen MV; Masmas TN; Nielsen M; Thiim M; Garred P; Stryhn A; Lund O; Buus S; Vindelov L
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1370-81. PubMed ID: 20353833
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
[TBL] [Abstract][Full Text] [Related]
5. Immunomonitoring of graft-versus-host minor histocompatibility antigen correlates with graft-versus-host disease and absence of relapse after graft.
Laurin D; Hannani D; Pernollet M; Moine A; Plumas J; Bensa JC; Cahn JY; Garban F
Transfusion; 2010 Feb; 50(2):418-28. PubMed ID: 19843288
[TBL] [Abstract][Full Text] [Related]
6. The impact of HLA-E polymorphisms in graft-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation.
Hosseini E; Schwarer AP; Ghasemzadeh M
Iran J Allergy Asthma Immunol; 2012 Mar; 11(1):15-21. PubMed ID: 22427472
[TBL] [Abstract][Full Text] [Related]
7. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
8. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
9. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
10. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210
[TBL] [Abstract][Full Text] [Related]
11. Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation.
Kornblit B; Masmas T; Petersen SL; Madsen HO; Heilmann C; Schejbel L; Sengeløv H; Müller K; Garred P; Vindeløv L
Biol Blood Marrow Transplant; 2010 Feb; 16(2):239-52. PubMed ID: 19819342
[TBL] [Abstract][Full Text] [Related]
12. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.
Teshima T; Matsuo K; Matsue K; Kawano F; Taniguchi S; Hara M; Hatanaka K; Tanimoto M; Harada M; Nakao S; Abe Y; Wake A; Eto T; Takemoto Y; Imamura M; Takahashi S; Ishida Y; Kanda Y; Kasai M; Takaue Y
Br J Haematol; 2005 Aug; 130(4):575-87. PubMed ID: 16098073
[TBL] [Abstract][Full Text] [Related]
13. Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Willems E; Humblet-Baron S; Dengis O; Seidel L; Beguin Y; Baron F
Bone Marrow Transplant; 2010 Sep; 45(9):1442-8. PubMed ID: 20062090
[TBL] [Abstract][Full Text] [Related]
14. Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate.
Murphy N; Diviney M; Szer J; Bardy P; Grigg A; Hoyt R; King B; Macgregor L; Holdsworth R; McCluskey J; Tait BD
Bone Marrow Transplant; 2006 Apr; 37(8):773-9. PubMed ID: 16518429
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM
Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611
[TBL] [Abstract][Full Text] [Related]
17. Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children.
Kałwak K; Porwolik J; Mielcarek M; Gorczyńska E; Owoc-Lempach J; Ussowicz M; Dyla A; Musiał J; Paździor D; Turkiewicz D; Chybicka A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1388-401. PubMed ID: 20382248
[TBL] [Abstract][Full Text] [Related]
18. Effect of donor CTLA-4 alleles and haplotypes on graft-versus-host disease occurrence in Tunisian patients receiving a human leukocyte antigen-identical sibling hematopoietic stem cell transplant.
Sellami MH; Bani M; Torjemane L; Kaabi H; Ladeb S; Ben Othmane T; Hmida S
Hum Immunol; 2011 Feb; 72(2):139-43. PubMed ID: 21081144
[TBL] [Abstract][Full Text] [Related]
19.
Bykova NA; Malko DB; Efimov GA
Front Immunol; 2018; 9():1819. PubMed ID: 30166983
[TBL] [Abstract][Full Text] [Related]
20. Immunogenic disparities of 11 minor histocompatibility antigens (mHAs) in HLA-matched unrelated allogeneic hematopoietic SCT.
Markiewicz M; Siekiera U; Karolczyk A; Szymszal J; Helbig G; Wojnar J; Dzierzak-Mietla M; Kyrcz-Krzemien S
Bone Marrow Transplant; 2009 Feb; 43(4):293-300. PubMed ID: 18850018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
